Daratumumab for the Treatment of Multiple Myeloma.

about

CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma

P2860

Q57191729-6B5DC55E-2243-42CC-AB28-2387072033AC Q59136966-7B638D87-AE58-42DE-B23E-9E42A5BCDF2F

P2860

Daratumumab for the Treatment of Multiple Myeloma.

Item

http://www.wikidata.org/entity/Q55337411

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Daratumumab for the Treatment of Multiple Myeloma.

@en

Daratumumab for the Treatment of Multiple Myeloma.

@nl

type

Item

label

Daratumumab for the Treatment of Multiple Myeloma.

@en

Daratumumab for the Treatment of Multiple Myeloma.

@nl

prefLabel

Daratumumab for the Treatment of Multiple Myeloma.

@en

Daratumumab for the Treatment of Multiple Myeloma.

@nl

P1476

Daratumumab for the Treatment of Multiple Myeloma.

@en

P2093

Jakub Krejcik

http://www.w3.org/2001/XMLSchema#string

Torben Plesner

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

NAD⁺-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

Robust isolation of malignant plasma cells in multiple myeloma.

Resolving the daratumumab interference with blood compatibility testing.

Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.

P304

1228

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.3389/FIMMU.2018.01228

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-06-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29915586

http://www.w3.org/2001/XMLSchema#string

P921

P932

5994592

http://www.w3.org/2001/XMLSchema#string

Daratumumab for the Treatment of Multiple Myeloma.

about

P2860

P2860

Daratumumab for the Treatment of Multiple Myeloma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P478

P577

P698

P921

P932